MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$8,700
Net Income
-$20,319,272
Net Profit Margin
-233554.85%
EPS
-$0.15
Unit: Dollar
Revenue Breakdown
cost of goods and services sold
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Revenues, net
8,700
127,439
-1,207,833
-3,102,431*
Cost of revenues
16,965
149,327
29,626
36,885*
Gross profit
-8,265
-21,888
-1,237,459
-3,139,316*
Research and development
3,251,099
4,500,520
3,634,352
5,776,522*
Selling, general and administrative
7,550,845
9,504,579
8,612,141
10,899,788*
Loss from operations
-10,810,209
-14,026,987
-13,483,952
-19,815,626*
Loss (gain) on equity method investment
-41,013
-45,119
-38,634
-48,355*
Interest income
-
-
-
22,434.5*
Interest (income) expense, net
7
3
0
-135,075*
Gain from change in fair value of promissory notes
1,103,000
-2,495,400
6,743,736
-897,345*
Warrant inducement expenses (note 10)
-
-
-
8,380,468.5*
(gain) loss from change in fair value of warrant liability
7,036,009
-6,838,022
2,791,813
-25,104,430.75*
(gain) loss on extinguishment of debt
-1,329,048
285,600
-
-
Net loss before income taxes
-20,319,272
-4,453,081
-
-2,355,314.25*
Income tax (benefit) expense
-
-
-
-387,957.25*
Net loss
-20,319,272
-4,453,081
-23,058,135
-1,967,357
Basic EPS
-0.15
-0.05
-0.38
-0.06
Diluted EPS
-0.15
-0.05
-0.38
-0.06
Basic Average Shares
136,743,333
81,835,900
60,205,035
32,635,658
Diluted Average Shares
136,743,333
81,835,900
60,205,035
32,635,658
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net loss
-$20,319,272
(-0.83%↓ Y/Y)
Net loss before
income taxes
-$20,319,272
(-0.83%↓ Y/Y)
Interest (income)
expense, net
$7
(100.01%↑ Y/Y)
Loss from operations
-$10,810,209
(31.36%↑ Y/Y)
(gain) loss from change
in fair value of...
$7,036,009
(251.87%↑ Y/Y)
(gain) loss on
extinguishment of debt
-$1,329,048
Gain from change in
fair value of...
$1,103,000
(-52.54%↓ Y/Y)
Loss (gain) on equity
method investment
-$41,013
(-32.80%↓ Y/Y)
cost of goods and
services sold
$16,965
Selling, general and
administrative
$7,550,845
(-21.99%↓ Y/Y)
Research and development
$3,251,099
(-54.43%↓ Y/Y)
Gross profit
-$8,265
(-100.78%↓ Y/Y)
Revenues, net
$8,700
(-99.42%↓ Y/Y)
gross profit
-$8,265
Cost of revenues
$16,965
(-96.14%↓ Y/Y)
Buy us a coffee
Outlook Therapeutics, Inc. (OTLK)
Outlook Therapeutics, Inc. (OTLK)